35.1(top 1%)
Impact Factor
38.3(top 1%)
extended IF
151(top 2%)
H-Index
2.5K
authors
2.1K
papers
98.1K
citations
5.8K
citing journals
70.9K
citing authors

Most Cited Articles of Lancet Respiratory Medicine,the

TitleYearCitations
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study20205.6K
Pathological findings of COVID-19 associated with acute respiratory distress syndrome20205K
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?20201.7K
Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study20151.2K
Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 201520171.1K
Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations2020812
Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis2019730
Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans2020727
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials2015715
COVID-19 cytokine storm: the interplay between inflammation and coagulation2020685
Rational use of face masks in the COVID-19 pandemic2020652
Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials2014596
E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis2016566
Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit2014566
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial2016487
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials2015474
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy2020469
Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial2020461
Respiratory risks from household air pollution in low and middle income countries2014459
Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial2015457
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper2018452
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data2014405
Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial2014400
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial2019398
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes2020395